Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(18 sites)
China
Suzhou Municipal Hospital of Anhui Province, Suzhou, Anhui Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Taikang Xian People's Hospital, Zhoukou, Henan WuYuan County People's Hospital, Bayan Nur, Inner Mongolia Huai'an First People's Hospital, Huai'an, Jiangsu Jiangsu Province (Suqian) Hospital, Suqian, Jiangsu Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, Jiangsu Changshu No.1 People's Hospital, Suzhou, Jiangsu First People's Hospital of Kunshan, Suzhou, Jiangsu Suzhou Ninth People's Hospital, Suzhou, Jiangsu Suzhou Xiangcheng People's Hospital, Suzhou, Jiangsu Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, Jiangsu Zhangjiagang Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu Taixing Second People's Hospital, Taizhou, Jiangsu Nuclear Industry 417 Hospital, Xi'an, Shaanxi First People's Hospital of Xianyang, Xianyang, Shaanxi Second Hospital of Tianjin Medical University, Tianjin